Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07582198 · ClinicalTrials.gov registry record · NA
Hearing Outcomes With the Nucleus® 8 Sound Processor and Nucleus® 7 Sound Processor in Adult Veteran and Non-veteran Cochlear Implant Recipients
A NA study, sponsored by Cochlear.
- Not yet
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT07582198: Clinical Trial NA study, sponsored by Cochlear.
NCT07582198 is a NA study that has not yet begun recruiting, run by Cochlear. The registered enrollment target is 26 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07582198, a NA study, has not yet begun recruiting, sponsored by Cochlear.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
The main purpose of this study is to understand how well a noise reduction feature called ForwardFocus works when used with two different sound processors: the Nucleus® 8 Sound Processor and the Nucleus® 7 Sound Processor, in adults with cochlear implants. The study will include two groups of adult cochlear implant recipients: veterans and non-veterans. Comparing these groups will help researchers understand how these sound processors perform in veteran populations as well as the broader adult cochlear implant community. Participants will use each sound processor and then take part in speech understanding tests in background noise. They will also complete questionnaires about their listening experiences with each processor.
Primary Outcome
The AzBio sentence test is a validated test used to assess open-set sentence recognition. AzBio sentences are spoken in a conversational style with limited contextual cues that the listener can use to predict unintelligible words.
Interventions
- DEVICE Nucleus 7 Sound Processor
- DEVICE Nucleus 8 Sound Processor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2026-05 |
| Est. Completion | 2026-09 |
| Phase | NA |
What is known before NCT07582198 opens enrollment
NCT07582198 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Nucleus 7 Sound Processor is the first listed.
NCT07582198 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07582198 about?
NCT07582198 is a clinical study titled "Hearing Outcomes With the Nucleus® 8 Sound Processor and Nucleus® 7 Sound Processor in Adult Veteran and Non-veteran Cochlear Implant Recipients". The main purpose of this study is to understand how well a noise reduction feature called ForwardFocus works when used with two different sound processors: the Nucleus® 8 Sound Processor and the Nucleus® 7 Sound Processor, in adults with cochlear implants. The study will include two groups of adult...
What is the current status of trial NCT07582198?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 26 participants. The study started on 2026-05. Estimated completion is 2026-09.
What interventions are being tested in trial NCT07582198?
The interventions under investigation include: Nucleus 7 Sound Processor (DEVICE), Nucleus 8 Sound Processor (DEVICE).
Who is sponsoring clinical trial NCT07582198?
This trial is sponsored by Cochlear, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07582198's enrollment target sits among peer trials
26 1710th of 2000 higher than 289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia